Opportunities and risks of large language models in digital interventions for substance use disorders.
Large language models (LLMs) are increasingly integrated into digital mental health tools, yet their role in substance use disorder (SUD) interventions remains poorly understood. This review synthesizes emerging evidence on the opportunities and risks of applying LLMs across the digital SUD care continuum.
Studies report promising applications in early detection, personalized support, continuous monitoring, and relapse prevention. LLMs demonstrate capacity to extract substance-use signals from natural language, generate supportive and motivational responses, and interpret narrative data for patient-reported outcomes. However, risks are substantial. LLMs can produce inaccurate or hallucinated content, may reinforce stigma or demographic bias, and can generate misleading or potentially unsafe advice. Privacy concerns are amplified in SUD contexts, where sensitive data are often managed outside regulated healthcare systems. Existing regulatory frameworks such as the EU AI Act or U.S. device regulations, do not yet provide clear governance for anonymous, AI-supported SUD interventions.
LLMs have potential to expand scalable, low-threshold support for SUDs, but their safe deployment requires validation, bias mitigation, transparent data governance, and robust human oversight. Evidence remains preliminary, and clinical integration should proceed cautiously.
Studies report promising applications in early detection, personalized support, continuous monitoring, and relapse prevention. LLMs demonstrate capacity to extract substance-use signals from natural language, generate supportive and motivational responses, and interpret narrative data for patient-reported outcomes. However, risks are substantial. LLMs can produce inaccurate or hallucinated content, may reinforce stigma or demographic bias, and can generate misleading or potentially unsafe advice. Privacy concerns are amplified in SUD contexts, where sensitive data are often managed outside regulated healthcare systems. Existing regulatory frameworks such as the EU AI Act or U.S. device regulations, do not yet provide clear governance for anonymous, AI-supported SUD interventions.
LLMs have potential to expand scalable, low-threshold support for SUDs, but their safe deployment requires validation, bias mitigation, transparent data governance, and robust human oversight. Evidence remains preliminary, and clinical integration should proceed cautiously.